Shares of Senseonics Holdings Inc (NYSEAMERICAN:SENS) have earned an average recommendation of “Hold” from the eight research firms that are presently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $6.00.

A number of research firms recently weighed in on SENS. Piper Jaffray Companies began coverage on shares of Senseonics in a research note on Tuesday, January 29th. They issued a “neutral” rating on the stock. Zacks Investment Research cut shares of Senseonics from a “hold” rating to a “sell” rating in a research note on Wednesday, February 6th.

NYSEAMERICAN:SENS opened at $1.95 on Thursday. Senseonics has a 52-week low of $1.93 and a 52-week high of $5.29.

Senseonics (NYSEAMERICAN:SENS) last posted its quarterly earnings data on Tuesday, March 12th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.11. The company had revenue of $7.20 million for the quarter, compared to the consensus estimate of $7.89 million.

A number of hedge funds and other institutional investors have recently bought and sold shares of SENS. BlackRock Inc. grew its stake in Senseonics by 6.1% during the fourth quarter. BlackRock Inc. now owns 6,142,950 shares of the company’s stock worth $15,910,000 after buying an additional 352,590 shares during the last quarter. Vanguard Group Inc grew its stake in Senseonics by 8.7% during the third quarter. Vanguard Group Inc now owns 4,779,370 shares of the company’s stock worth $22,797,000 after buying an additional 382,058 shares during the last quarter. Vanguard Group Inc. grew its stake in Senseonics by 8.7% during the third quarter. Vanguard Group Inc. now owns 4,779,370 shares of the company’s stock worth $22,797,000 after buying an additional 382,058 shares during the last quarter. Massachusetts Financial Services Co. MA grew its stake in Senseonics by 19.9% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 3,696,533 shares of the company’s stock worth $9,574,000 after buying an additional 613,995 shares during the last quarter. Finally, City Financial Investment Co Ltd grew its stake in Senseonics by 38.2% during the fourth quarter. City Financial Investment Co Ltd now owns 1,450,000 shares of the company’s stock worth $3,756,000 after buying an additional 401,000 shares during the last quarter. 30.66% of the stock is currently owned by institutional investors and hedge funds.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days.

Recommended Story: What is a Buy-Side Analyst?

Analyst Recommendations for Senseonics (NYSEAMERICAN:SENS)

Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.